尿道周围钙化可作为前列腺SBRT后急性泌尿生殖毒性的潜在生物标志物
本研究回顾性分析60例接受根治性SBRT的局限期前列腺腺癌患者,在计划CT上评估尿道周围钙化(PUC),发现PUC与急性≥2级泌尿生殖(GU)毒性独立相关(调整OR 6.90)。PUC评估可能成为简单、零成本的影像生物标志物用于治疗前风险分层。
要点
- PUC在计划CT上可识别,观察者间一致性高(κ=0.84)。
- 有PUC患者急性≥2级GU毒性发生率显著更高(64.7% vs 23.3%)。
- 调整基线IPSS后,PUC仍独立关联GU毒性(调整OR 6.90)。
核心结论
- 计划CT上的尿道周围钙化与前列腺SBRT后急性≥2级GU毒性独立相关。
- 若经外部验证,PUC评估可能作为治疗前尿路毒性风险分层的简单、零成本影像生物标志物。
研究设计与样本
- 回顾性分析60例2023年6月至2026年2月接受根治性SBRT的局限期前列腺腺癌患者。
- 由盲法观察者依据预设标准在平扫计划CT上评估PUC。
- 主要终点为治疗期间或90天内发生的急性≥2级GU毒性,按CTCAE v5分级。
- 采用逻辑回归评估关联,多变量分析使用Firth惩罚回归。
主要发现
- 17例(28.3%)患者检出PUC,观察者间一致性高(93.3%;Cohen's κ=0.84)。
- 21例(35%)发生急性≥2级GU毒性,其中3例(5%)为≥3级。
- 有PUC者急性≥2级GU毒性发生率显著高于无PUC者(64.7% vs 23.3%;OR 6.05,95%CI 1.78-20.51;P=0.006)。
- 调整基线IPSS后,PUC仍独立关联毒性(调整OR 6.90,95%CI 1.97-27.96;P=0.002)。
- 基线IPSS亦独立关联毒性(每分调整OR 1.13;P=0.008)。
关键数值与推荐
- PUC检出率28.3%(17/60),观察者间一致性93.3%(κ=0.84)。
- 急性≥2级GU毒性总体发生率35%(21/60),≥3级为5%(3/60)。
- 有PUC者急性≥2级GU毒性64.7%,无PUC者23.3%(OR 6.05,95%CI 1.78-20.51;P=0.006)。
- 调整IPSS后PUC的调整OR 6.90(95%CI 1.97-27.96;P=0.002)。
- 基线IPSS每增加1分的调整OR 1.13(P=0.008)。
临床怎么用
- 在前列腺SBRT治疗前计划CT上可常规评估尿道周围钙化。
- PUC阳性且基线IPSS较高的患者急性GU毒性风险更高,可考虑加强 pretreatment 风险告知与随访。
- PUC评估简单、零成本,但需外部验证后方可用于临床风险分层。
局限性
- 回顾性单中心设计,样本量60例。
- PUC评估依赖观察者,虽一致性高但仍需外部验证。
- 未报告外部验证结果,结论尚不能直接推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Peri-urethral calcifications (PUCs) are readily identifiable on planning computed tomography (CT) and may reflect chronic inflammation, fibrosis, and reduced peri-urethral tissue compliance. We evaluated whether baseline PUCs are associated with acute genitourinary (GU) toxicity following prostate stereotactic body radiotherapy (SBRT). METHODS: We retrospectively analyzed 60 consecutive patients with localized prostate adenocarcinoma treated with definitive SBRT between June 2023 and February 2026. PUCs were assessed on non-contrast planning CT using predefined criteria by blinded observers. The primary endpoint was acute grade ≥ 2 GU toxicity occurring during treatment or within 90 days, graded according to CTCAE v5. Associations with toxicity were evaluated using logistic regression, with Firth penalized regression used for multivariable analysis. RESULTS: PUCs were identified in 17 patients (28.3%). Interobserver agreement was high (93.3%; Cohen's κ = 0.84). Overall, 21 patients (35%) developed acute grade ≥ 2 GU toxicity, including three (5%) with grade ≥ 3 toxicity. Acute grade ≥ 2 GU toxicity occurred significantly more frequently in patients with PUCs than in those without PUCs (64.7% vs 23.3%; OR 6.05, 95% CI 1.78-20.51; P = 0.006). After adjustment for baseline International Prostate Symptom Score (IPSS), PUCs remained independently associated with toxicity (adjusted OR 6.90, 95% CI 1.97-27.96; P = 0.002). Baseline IPSS was also independently associated with toxicity (adjusted OR 1.13 per point; P = 0.008). CONCLUSION: PUCs on routine planning CT were independently associated with acute grade ≥ 2 GU toxicity after prostate SBRT. If externally validated, PUC assessment may provide a simple, cost-neutral imaging biomarker for pretreatment urinary toxicity risk stratification.
引用
- Awad M, Massalha I, Tova Y, et al. Peri-urethral calcifications as a potential biomarker for acute genitourinary toxicity following prostate stereotactic body radiotherapy. Clin Transl Radiat Oncol. 2026. PMID: 42959402. doi:10.1016/j.ctro.2026.101311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。